A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.

Marc GeirnaertJacy HowarthKristen MartinChad RicardScott StreileinDanica WasneyVi DaoRami KotbEmily RimmerLeonard Minuk

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Our experience of daratumumab infusions using a split dose approach was associated with an infusion-related reaction rate in 28% of patients on cycle 1, day 1 of DVd and DRd regimens. All patients were able to complete full doses of daratumumab by utilizing split dose. The rates of daratumumab infusion-related reactions are highest on the first infusion. In addition, our adoption of rapid infusion daratumumab was safe.

Keyphrases

multiple myeloma
low dose
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
cross sectional